Raymond James Issues Negative Estimate for TSE:MDP Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities research analysts at Raymond James cut their FY2027 EPS estimates for Medexus Pharmaceuticals in a note issued to investors on Monday, February 3rd. Raymond James analyst M. Freeman now expects that the company will post earnings of $0.74 per share for the year, down from their prior estimate of $0.88. Raymond James has a “Strong-Buy” rating and a $4.00 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other research analysts have also weighed in on the company. Ventum Financial increased their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Stifel Nicolaus boosted their target price on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a report on Thursday, January 30th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Stock Down 19.5 %

Shares of MDP opened at C$3.05 on Wednesday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56. The company’s fifty day moving average is C$3.52 and its two-hundred day moving average is C$2.82. The firm has a market cap of C$74.82 million, a PE ratio of 61.00 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.